

Wavefront – guided laser – assisted subepithelial keratectomy in low myopia, myopic astigmatism and high myopia

Seyed Javad Hashemian¹, Abbas Sheikh–Hassani¹, Alireza Foroutan¹, Mohammad Jafar Ghempanah¹, Mohammad Ebrahim Jafari¹, Mahsa Sadat Hashemian², Shadrokh Nabili³

¹Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran 1666718853, Iran

²Pharmacy School, Iran University of Medical Sciences, Tehran 1666718853, Iran

³University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, Kendal LA1 4RP, UK

Correspondence to: Seyed Javad Hashemian. Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, No. 86, 10th Boostan Street, Pasdaran Avenue, Tehran 1666718853, Iran. sj_hashemian@yahoo.com

Received:2012–11–17 Accepted:2014–11–04

应用波前像差引导的 LASEK 治疗近视散光 and 低、高度近视

Seyed Javad Hashemian¹, Abbas Sheikh–Hassani¹, Alireza Foroutan¹, Mohammad Jafar Ghempanah¹, Mohammad Ebrahim Jafari¹, Mahsa Sadat Hashemian², Shadrokh Nabili³ (作者单位:¹伊朗,德黑兰 1666718853,伊朗医科大学,Rassoul Akram 医院眼科研究中心;²伊朗,德黑兰 1666718853,伊朗医科大学药学院;³英国,兰开斯特,肯德尔 LA1 4RP, Morecambe Bay NHS 信托会大学医院)

通讯作者:Seyed Javad Hashemian. sj_hashemian@yahoo.com

摘要

目的:对比在矫正低度近视,近视散光和高度近视时应用波前像差引导的激光上皮瓣下角膜磨镶术(LASEK)的安全性,有效性,可预测性,稳定性和并发症。

方法:该回顾性分析共纳入416眼,分为3组,低度近视组159眼,等值球镜 $-3.68\pm 1.33\text{D}$;近视散光组161眼,等值球镜 $-5.99\pm 2.24\text{D}$,柱镜度 $2.41\pm 1.07\text{D}$;高度近视组96眼,等值球镜 $-7.41\pm 0.80\text{D}$ 。制瓣后,进行波前像差为基础的准分子激光切削术。在术后10d,2,6和12mo后评估其安全性,有效性,可预测性和稳定性。

结果:术后12mo,低度近视组等值球镜 $-0.36\pm 0.31\text{D}$,近视散光组 $0.15\pm 0.41\text{D}$,高度近视组 $0.58\pm 0.68\text{D}$ 。低度近视组中,裸眼视力为20/20的患者占90.60%,近视散光组78.90%,高度近视组67%。疗效指标在三组中分别为0.98,1.04和0.92。安全性指标分别为1.00,1.07和1.05。低度近视组有5眼(3.1%)最佳矫正视力提升1行,近视散光组有44眼(27.3%)提升1~3行,高度近视组18眼

(19.2%)提升1~2行。低度近视组只有2例产生角膜雾状混浊。在疗效和安全性方面三组比较均无统计学差异。

结论:波前像差引导的激光上皮瓣下角膜磨镶术是治疗低度近视,近视散光和高度近视的一种有效安全的方法,而在治疗近视散光时其可预测性、有效性和安全性更佳。

关键词:波前像差引导;激光上皮瓣下角膜磨镶术;近视;散光;激光视力矫正

引用:Hashemian SJ, Sheikh–Hassai A, Foroutan A, Ghempanah MJ, Jafari ME, Hashemian MS, Nabili S.应用波前像差引导的LASEK治疗近视散光 and 低、高度近视. 国际眼科杂志 2015;15(2):192–197

Abstract

• **AIM:** To compare the safety, efficacy, predictability, stability and complications of wavefront–guided laser–assisted subepithelial keratectomy (LASEK) in low myopia, myopic astigmatism and high myopia correction.

• **METHODS:** A retrospective analysis of 416 eyes were assigned to 3 groups: 159 eyes with low myopia (LM) and mean refractive spherical equivalent (MRSE) of -3.68 ± 1.33 dioptre (D); 161 eyes with myopic astigmatism (MA) and MRSE of $-5.99\pm 2.24\text{D}$ and mean cylinder of $2.41\pm 1.07\text{D}$; and 96 eyes with high myopia (HM) and MRSE of $-7.41\pm 0.80\text{D}$. After an epithelial flap creation, a wavefront–based excimer laser ablation was performed. Safety, efficacy, predictability and stability were evaluated at day 10, 2, 6 and 12mo postoperatively.

• **RESULTS:** At 12mo, the MRSE was $-0.36\pm 0.31\text{D}$ in LM group, $0.15\pm 0.41\text{D}$ in MA group and $0.58\pm 0.68\text{D}$ in HM group. The uncorrected visual acuity (UCVA) was 20/20 in 90.60% of patients in LM group, 78.90% in MA group and 67% in HM group. Efficacy indices were 0.98, 1.04 and 0.92 in LM, MA and HM groups, respectively. Safety indices were 1.00, 1.07 and 1.05 in LM, MA and HM respectively. Five eyes (3.1%) in the LM group gained 1 line. Forty–four eyes (27.3%) in MA gained 1–3 lines and eighteen eyes (19.2%) of HM group gained 1–2 lines of BSCVA. Only 2 eyes in LM group developed corneal haze. There were not statistically significant differences in efficacy and safety indices amongst three groups.

• **CONCLUSION:** Wavefront-guided LASEK is an effective and safe procedure for the treatment of LM, MA, and HM. although in myopic astigmatism the predictability, efficacy and safety indices had been better.

• **KEYWORDS:** wavefront - guided; laser - assisted subepithelial keratectomy; myopia; astigmatism; laser vision correction

DOI:10.3980/j.issn.1672-5123.2015.2.02

Citation: Hashemian SJ, Sheikh - Hassai A, Foroutan A, Ghempanah MJ, Jafari ME, Hashemian MS, Nabili S. Wavefront-guided laser - assisted subepithelial keratectomy in low myopia, myopic astigmatism and high myopia. *Guoji Yanke Zazhi (Int Eye Sci)* 2015;15(2):192-197

INTRODUCTION

Surface ablation has been established as a safe method for correcting refractive errors. Surface ablation procedures including photorefractive keratectomy (PRK) and laser - assisted subepithelial keratectomy (LASEK) have gained popularity due to the elimination of flap complications and the reduction of postoperative corneal ectasia^[1]. Corneal haze is a major complication associated with surface ablation; however, the use of mitomycin C (MMC) 0.02% solution (12s to 2min) has reduced the chance of corneal haze in eyes with higher risk of this complication^[1-8]. It is well known that conventional surface ablation procedures and laser-assisted *in situ* keratomileusis (LASIK) increases higher order aberrations (HOAs), which explains visual symptoms such as glare and halos, despite the apparent success of surgery^[9-11]. Preoperative wavefront analysis has been used to create individualized ablation patterns to compensate for pre-existing aberration^[12-14]. Although the true clinical significance of HOAs is not fully understood, HOAs may have a role in degradation of retinal image especially in mesopic vision^[15-18]. Wavefront - guided LASEK may improve the quality of vision and reduce the amount of aberration after corneal refractive surgery^[19-23]. The effectiveness, predictability, stability and safety of wavefront - guided PRK for low and moderate myopia have been widely reported. The present study evaluates the safety, efficacy, predictability, stability and complications of wavefront - guided LASEK for low myopia (LM), myopic astigmatism (MA) and high myopia (HM).

SUBJECTS AND METHODS

A retrospective chart review was developed containing data of patients underwent customized surface ablation from December 2005 to December 2007. All surgeries were performed by the same surgeon (SJH). The Review Board of Eye Research Centre in Iran University of Medical Sciences approved this study.

The data-containing age, sex, date of surgery, spherical equivalent refraction, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) were collected.

The inclusion criteria for each group were stable refraction for at least 6mo prior to the surgery, the post-ablation of residual

corneal thickness of more than 350 μ m without epithelium and the discontinuation of contact lenses for at least 1mo prior to ocular examination to eliminate the warping effect on the cornea.

The exclusion criteria included history of previous refractive procedures, keratoconus, cataract surgery, diabetes mellitus, glaucoma, connective tissue disorders, retinal disease, dry eye, amblyopia, pregnancy and breast-feeding periods.

Patients that did not complete whole follow up periods were excluded from the study.

Preoperatively all patients had a complete ophthalmic examination including UDVA and CDVA using Snellen chart with the same light condition, manifest, subjective and cycloplegic refractions, Goldmann applanation tonometry, slit lamp assessment, pachymetry, topography, aberrometry and dilated indirect ophthalmoscopy.

At this study all eyes aberration was assessed with Zywave aberrometer (Bausch & Lomb, Rochester, New York, USA) based on the Hartmann - Shack principle. The same experienced examiner performed all wavefront measurements. Optical aberrations were measured with a dilated pupil (>6mm) 20min after instillation of topical 0.5% Tropicamide drop (Sina Darou, Tehran, Iran). Each eye was tested 3 times by Zywave aberrometer. The best image was included in the study based on the image quality. If refraction of the patient was in the range (spherical dioptre: ± 0.75 D, cylindrical dioptre: ± 0.5 D and astigmatic axis: $\pm 15^\circ$) of subjective refraction, it was included in the study and HOAs and root mean square (RMS) values were documented.

The corneal data sets including pachymetry, anterior and posterior elevation maps were analysed with Orbscan IIz (Bausch & Lomb, Rochester, USA).

Surgical Technique LASEK was performed under topical anesthesia with Anestocaine (Tetracaine HCL 0.5%, Sina Darou, Tehran, Iran). An alcohol solution cone (J2905, Janach, UK) with an 8.5mm diameter was placed on the cornea. An ethyl alcohol 20% solution was instilled inside the cone and left for about 20s. All alcohol was carefully absorbed using a dry sponge and thoroughly washed off with balanced salt solution. The epithelial flap was gently lifted with an epithelial micro hook and peeled back as a single sheet toward the 12 o'clock position. Excimer laser ablation was performed by Technolas 217z excimer laser (Technolas Perfect Vision, St Louis, USA) using a wavefront-guided ablation algorithm with iris registration. Following laser ablation, MMC 0.02% solution was applied for 12s in eyes with more than 60.0 micron tissue ablation. In patients with more than 6.0D spherical equivalent, spherical refractive errors was under corrected by 10%. The flap was washed with balanced salt solution and then carefully repositioned. All eyes were fitted with an AirOptix® Night & Day® AQUA contact lens (CIBA VISION, Novartis AG Company, USA). A drop of Ciprolex (Ciprofloxacin 0.3%, Sina Darou, Tehran, Iran) and a drop of Betasonathe (Betamethasone disodium Phosphate 0.1%, Sina Darou, Tehran, Iran) were applied at the conclusion of

Table 1 Patients demographics and preoperative data

Parameters	Low myopia	Myopic astigmatism	High myopia	$\bar{x} \pm s$ <i>P</i>
Age (a, range)	27.39±6.96 (18-52)	27.24±7.30 (18-49)	26.03±7.81 (18-49)	NS
F/M (<i>n</i> , %)	117 (73.6)/42 (26.4)	125 (77.6)/36 (22.4)	75 (78.1)/21 (21.9)	NS
Follow-up (mo)	>12	>12	>12	NS
Preoperative keratometry (Dioptre)	43.98±1.26 (40.75-48.25)	44.20±1.43 (39.75-47.50)	43.94±1.31 (40.50-47.00)	NS
Preoperative pachymetry (Micron)	541.8±33.8 (480-640)	542.5±35.5 (480-660)	547.2±31.8 (480-630)	NS

NS; Non-significant.

procedure. Postoperative medications include Ciprox drops (Ciprofloxacin 0.3%, Sina Darou, Tehran, Iran) 4 times a day for 1wk and Fluometholon 0.1% drops (Sina Darou, Tehran, Iran) 4 times per day for 1mo, 3 times for 1mo, 2 times for 1mo, once per day for 1mo. In addition, all patients were prescribed hypromellose 0.32% minims (Dr Gerhard Mann Chem-pharm Fabrik GmbH, 13581 Berlin, Germany) 4 times per day for 2mo. Postoperatively, the eyes were checked daily. Following complete closure of epithelial defect, bandage contact lens was removed usually after 3d.

Statistical Analysis This study presented the result by utilising mean, standard deviation, median and range in addition to one-way ANOVA in order to analyse the differences between the sets and the probability value. *P* value of less than 0.05 was considered to be statistically significant. All statistical analysis was performed by SPSS (version 20) software and Chi-square test was used for the qualitative data comparison.

RESULTS

The mean ages of low myopic group, myopic astigmatism group and high myopic group were 27.39 (range 18-52y), 27.24 (range 18-49y) and 26.03 (range 18-49y), respectively (*P* = 0.306). A total of 416 eyes were categorised to low myopia with spherical equivalent (SE) of <-6.00D (range -1.00D to -600D) and astigmatism under 1D, myopic astigmatism with mean SE and astigmatism of -5.99±2.24D (range -1D to -9.25D) and -2.41±1.07D (range -1.25D to -5.00D) respectively and high myopic group with SE of >-6.00D and mean SE of -7.41±0.80D (range -6.25D to -9.5D) with astigmatism under -1.00D. Demographics and preoperative data of patients were shown in Table 1.

Predictability In the LM group, 95.2%, 99.4%, 99.5% and 99.4% of eyes were within 1D of target SE, at day 10 and 2, 6 and 12mo respectively. In the MA group, 90.1%, 98.2%, 98.8% and 97.9% of eyes were within 1D at the above-mentioned periods respectively and these figures were 90.7%, 97.9%, 92.7% and 83.9% at these intervals respectively in the HM group (Figure 1).

Postoperative spherical equivalent refraction was within ±0.5D of 94.3%, 86.3% and 62.4% of eyes in the LM, MA, and HM groups at month 12, respectively (Figures 1, 2).




Figure 1 Post-operative spherical equivalent refractive errors at the 12th month in low myopia, myopic astigmatism and high myopia groups.




Figure 2 One-year post-operative attempted and achieved spherical equivalent in low myopia, myopic astigmatism and high myopia All figures are in dioptre.

Safety The safety indices (postoperative CDVA/preoperative CDVA) were 1.00, 1.05 and 1.02 at 2mo in LM, MA and HM groups respectively. At 6mo, these figures were 1.003, 1.066 and 1.037 and at 12mo, we calculated them as 1.00, 1.07 and 1.05, respectively. In the LM group, 1 eye (0.6%) lost 2 lines of CDVA and 5 eyes (3.10%) gained 1 line of CDVA. In the MA group, no loss of CDVA was seen and 29 eyes (18.0%) gained 1 line, 13 eyes (8.1%) gained 2 lines and 2 eyes (1.2%) gained 3 lines of CDVA. In the HM group, 2 eyes (2.1%) lost 1 line of CDVA and 15 eyes

Table 2 Visual acuity outcomes at 10d, 2, 6 and 12mo

UDVA/snellen	10d postop.			2mo postop.			6mo postop.			12mo postop.		
	LM	MA	HM	LM	MA	HM	LM	MA	HM	LM	MA	HM
>20/20	62 ^a (48.4)	39 (32.5)	22 (33.3)	147 (92.5)	111 (68.9)	66 (68.8)	148 (93.1)	121 (75.2)	72 (75)	144 (90.6)	127 (78.9)	63 (67)
>20/25	112 (87.5)	94 (78.3)	45 (68.1)	157 (98.8)	149 (92.5)	86 (89.6)	156 (98.1)	151 (93.8)	87 (90.6)	155 (97.5)	152 (94.4)	73 (77.6)
>20/30	122 (95.3)	113 (94.1)	59(89.3)	157 (98.8)	161 (100)	90 (93.6)	156 (98.1)	161 (100)	92 (95.8)	155 (97.5)	161 (100)	81 (85.6)

^aNumber of patients (%) .

(16%) gained 1 line and 3 eyes (3.2%) gained 2 lines of CDVA (Figure 3). In the LM group, we had 2 eyes (1.2%) with haze formation grade 1–2 based on Fantes grading. Both eyes improved 4mo following surgery.

High intraocular pressure (IOP) (more than 25mmHg) was found in 3 eyes (1.9%) in LM group. In the MA group, we had only one case with high IOP but no case of haze formation. Amongst HM group patients, neither corneal haze nor high IOP was noted during 12mo follow up.

Efficacy The efficacy indices (postoperative UCVA/preoperative CDVA) in the LM, MA and HM groups were 0.98, 1.02 and 0.96 at 2mo and 0.98, 1.03 and 0.98 at 6mo. These figures were noted as 0.98, 1.04 and 0.92 at 12mo, respectively. This study found 90.6% of eyes in LM group, 78.9% of eyes in MA and 67.0% of eyes in HM groups achieved UCVA of 20/20 or better at the 12th month (Table 2).

Stability The UCVA of LM and MA groups showed no change at 2–12mo postoperatively. The SE in LM and MA groups also revealed no significant change during the above period; however, in HM group, UCVA and SE decreased from the second month to the twelfth month ($P < 0.05$) (Figure 4).

DISCUSSION

The aim of this study wasto compare the safety, efficacy, predictability, stability and complications of wavefront-guided LASEK in the treatment of low myopia, myopic astigmatism and high myopia.

It is believed that not only wavefront-guided LASEK may decrease the amount of induced aberrations and improve the quality of vision but also epithelial flap may decrease pain and improve epithelial healing following procedure^[5,10].

Safety data were excellent in three groups with safety indices of 1.00, 1.07 and 1.05 at 12mo in LM, MA and HM groups, respectively. The efficacy indices were 0.98, 1.04 and 0.92 at 12mo, respectively. The UCVA and SE of LM and MA groups show no change during 12mo of postoperative examination ($P < 0.05$). We also noted a considerable number of treated eyes *i. e.* 90.6% of LM eyes, 78.9% of MA eyes and 67.0% of HM eyes groups achieved UCVA of 20/20 or better after 12mo follow up.

In the LM group, only 1 eye (0.6%) lost 2 lines of CDVA and 5 eyes (3.1%) gained 1 line of CDVA after 1y. Postoperative SE was within $\pm 1.0D$ in 99.4% of eyes at 1y. Corneal haze formation was found in 1.2% (2 eyes) of patients. In the MA group, no eye lost any line of CDVA and 18.00% (29 eyes) gained 1 line of DCVA. In this cohort,




Figure 3 Changes in corrected distance visual acuity The X axis denotes the changes in reading Snellen charts lines and the Y axis shows the percentage of patients. No patients lost 3 or more lines on Snellen chart.




Figure 4 Stability of wavefront-guided LASEK in 416 eyes with low myopia, myopic astigmatism and high myopia groups. All figures denote spherical equivalents in dioptre.

97.9% of eyes were within $\pm 1D$ SE at the end of the study. In the HM group, 2.1% (2 eyes) lost 1 line of DCVA and 16.0% (15 eyes) gained 1 line of DCVA and post-operative SE were within $\pm 1D$ in 83.9% of eyes at 12mo. There was no case of haze formation in both MA and HM groups.

The interesting point was that there was 1.6% haze formation in LM group but no case of haze formation in MA and HM groups. This may be due to the usage of MMC 0.02% in patients with tissue ablation $\geq 60.0\mu m$ according to our treatment protocol.

Our co-authors (Hashemian SJ, Foroutan A, Ghempanah MJ, Jafari ME) at the other study^[24] assessed the visual and refractive outcomes of LASEK in low myopic eyes. They found UCVA was 20/20 or better in 96.1% eyes and 20/40 or better

in 99.52% respectively after 12mo.

Kohnen *et al*^[25] performed wavefront-guided LASIK in 97 eyes with a mean subjective manifest spherical equivalent of $-5.25 \pm 2.07D$ (range -0.24 to -9.00). UCVA was 20/20 or better in 83% of the eyes and 20/40 or better in 98% at 1-year postoperatively. During this period, no eyes lost 2 lines of corrected distance visual acuity (CDVA) and 40 eyes (40.81%) gained 1 line of CDVA and 5 eyes (5%) gained 2 lines. In comparison, our study signified the visual acuity was 20/20 or better in 78.8% in three groups, 11.77% gained 1 line, 3.8% gained 2 lines and 0.48% gained 3 lines of corrected distance visual acuity at 1y postoperatively. In 2009 de Benito-Llopis *et al*^[26] compared femtosecond assisted LASIK (FS-LASIK) in 1072 eyes with LASEK in 1036 eyes. Preoperative mean sphere and BSCVA were $-3.93D$ vs $-3.87D$ and 1.12 vs 1.12 in FS-LASIK and LASEK, respectively. UCVA was 0.92 vs 0.62 , 0.98 vs 0.78 , 0.96 vs 0.91 , and 1.06 vs 1.03 in FS-LASIK and LASEK, respectively, at 1d, 1wk, and 1 and 3mo after surgery ($P < 0.01$ for all comparisons). Three months postoperatively, BSCVA was 1.13 and 1.10, respectively ($P = 0.001$). At that stage, 20 eyes (1.93%) in the LASEK group vs 9 eyes (0.84%) in the FS-LASIK group had lost 2 or more lines of CDVA. Ten eyes (0.96%) in the LASEK group gained 2 or more lines of CDVA, whereas 3 eyes (0.28%) in the FS-LASIK group gained 2 lines. Six months postoperatively, only 2 LASEK eyes (0.19%) showed loss of 2 or more lines of CDVA, compared to 3 FS-LASIK treated eyes (0.28%). In our study, preoperative CDVA were 0.99 and 0.91 in LM and MA groups respectively. UCDVA were 0.97 and 0.95 and CDVA were 0.99 and 0.97 at 1 year postoperatively, respectively. Only 0.6% of eyes lost 2 lines in LM and no eye lost visual acuity in MA and 3.1% gained 1 line and 27.3% gained 1-3 lines of visual acuity in LM and MA groups at 1y postoperatively.

Sia *et al*^[27] reported the visual outcomes after Epi-LASIK and PRK for low and moderate myopia in 2012. Safety indices were 1.33 vs 1.29, efficacy indices were 0.85 vs 0.67, predictability were 86.2% vs 92.5%. And 75.9% vs 61.9% of eyes achieved UCDVA 20/20 or better at 12mo in epi-LASIK and PRK respectively after surgery. No eyes lost ≥ 2 lines of DCVA in either group at 12mo; whereas, at our study the safety indices in LM and MA groups were 1.00 and 1.07, efficacy indices were 0.98 and 1.04 and predictability indices were 99.4 and 97.9 within $\pm 1.0D$. UCDVA was 20/20 or better in 90.6% of LM eyes and in 78.9% of MA eyes at 1y follow up.

Teus *et al*^[28] reported the visual result of LASEK and epi-LASIK in 94 eyes (47 LASEK and 47 epi-LASIK) in myopic patients (range -0.5 to -9.00) in 2008. The UCVA, 3mo postoperatively, was 1.06 ± 0.1 and 1.03 ± 0.18 in LASEK

and epi-LASIK group respectively. UCVA was ≥ 1.0 in 78.7% of LASEK eyes and 65.9% of Epi-LASIK eyes three months after surgery. The safety indices were (0.99 ± 0.1) after LASEK and (0.93 ± 0.1) after Epi-LASIK ($P = 0.04$). The efficacy indices were (0.97 ± 0.1) and (0.89 ± 0.1) respectively ($P = 0.01$).

This study evaluates the visual outcomes in different types of myopic patients treated with wavefront-guided LASEK. Our results showed that wavefront-guided LASEK was a safe, effective and predictable procedure for treatment of low, moderate and high myopia. Visual and refractive outcomes of this technique were better in low myopia and myopic astigmatism groups compared to high myopic group.

REFERENCES

- 1 Taneri S, Feit R, Azar DT. Safety, efficacy, and stability indices of LASEK correction in moderate myopia and astigmatism. *J Cataract Refract Surg* 2004;30(10):2130-2137
- 2 Focal Point; American Academy of Ophthalmology, Volume XXVIII Number 2 March 2010 (module 2 of 3). Innovations in Advanced Surface Laser Refractive Surgery
- 3 Buzzonetti L, Iarossi G, Valente P, Volpi M, Petrocelli G, Scullica L. Comparison of wavefront aberration changes in the anterior corneal surface after laser-assisted subepithelial keratectomy and laser in situ keratomileusis; preliminary study. *J Cataract Refract Surg* 2004;30(9):1929-1933
- 4 de Benito-Llopis L, Teus MA, Sánchez-Pina JM, Hernández-Verdejo JL. Comparison between LASIK and LASEK for the correction of low myopia. *J Refract Surg* 2007;23(2):139-145
- 5 Lee HK, Lee KS, Kim JK, Kim HC, Seo KR, Kim EK. Epithelial healing and clinical outcomes in excimer laser photorefractive surgery following three epithelial removal techniques; mechanical, alcohol, and excimer laser. *Am J Ophthalmol* 2005;139(1):56-63
- 6 Camellin M, Wyler D. Epi-LASIK versus epi-LASEK. *J Refract Surg* 2008;24(1):S57-63
- 7 Litwak S, Zadok D, Garcia-de Quevedo V, Robledo N, Chayet AS. Laser assisted subepithelial keratotomy versus photorefractive keratectomy for the correction of myopia; a perospective comparative study. *J Cataract Refract Surg* 2002;28(8):1330-1333
- 8 Lee JB, Serong GJ, Lee JH, Seo KY, Lee YG, Kim EK. Comparison of laser epithelial keratomileusis and photorefractive keratectomy for low to moderate myopia. *J Cataract Refract Surg* 2001;27(4):565-570
- 9 Karimian F, Feizi S, Jafarinasab MR. Conventional versus custom ablation in photorefractive keratectomy; randomized clinical trial. *J Cataract Refract Surg* 2010;36(4):637-634
- 10 Miraftab M, Seyedian MA, Hashemi H. Wavefront-guided vs wavefront-optimized LASIK; a randomized clinical trial comparing contralateral eyes. *J Refract Surg* 2011;27(4):245-250
- 11 Nuijts RM, Nabar VA, Hament WJ, Eggink FA. Wavefront-guided versus standard laser in situ keratomileusis to correct low to moderate myopia. *J Cataract Refract Surg* 2002;28(11):1907-1913
- 12 Ghoreishi SM, Naderibeni A, Peyman A, Rismanchian A, Eslami F. Aspheric profile versus wavefront-guided ablation photorefractive keratectomy for the correction of myopia using the Allegretto Eye Q. *Eur J Ophthalmol* 2009;19(4):544-553
- 13 Arbelaez MC, Vidal C, Arba-Mosquera S. Clinical outcomes of corneal wavefront customized ablation strategies with SCHWIND CAM in

LASIK treatments. *Ophthalmic Physiol Opt* 2009;29(5):549–556

14 Gatinel D, Hoang-Xuan T, Azar DT. Determination of corneal asphericity after myopia surgery with the excimer laser; a mathematical model. *Invest Ophthalmol Vis Sci* 2001;42(8):1736–1742

15 Applegate RA, Thibos LN, Hilmantel G. Optics of aberroscopy and super vision. *J Cataract Refract Surg* 2001;27(7):1093–1107

16 Wang L, Koch DD. Ocular higher-order aberrations in individuals screened for refractive surgery. *J Cataract Refract Surg* 2003;29(10):1896–1903

17 Mrochen M, Kaemmerer M, Mierdel P, Seiler T. Increased higher-order optical aberrations after laser refractive surgery: a problem of subclinical decentration. *J Cataract Refract Surg* 2001;27(3):362–369

18 Moreno-Barriuso E, Lloves JM, Marcos S, Navarro R, Llorente L, Barbero S. Ocular aberrations before and after myopic corneal refractive surgery: LASIK-induced changes measured with laser ray tracing. *Invest Ophthalmol Vis Sci* 2001;42(6):1396–1403

19 George MR, Shah RA, Hood C, Krueger RR. Transitioning to optimized correction with the WaveLight ALLEGRETTO WAVE: case distribution, visual outcomes, and wavefront aberrations. *J Refract Surg* 2010;26(10):S806–813

20 Hashemi H, Fotouhi A, Foudazi H, Sadeghi N, Payvar S. Prospective randomized paired comparison of laser epithelial keratomileusis and photorefractive keratectomy for myopia less than -6.50 diopters. *J Refract Surg* 2004;20(3):217–222

21 Chung SH, Lee IS, Lee YG, Lee HK, Kim EK, Yoon G, Seo KY. Comparison of high order aberration after wavefront-guided laser *in situ* keratomileusis and laser-assisted subepithelial keratectomy. *J Cataract*

Refract Surg 2006;32(5):779–784

22 Venter J. Wavefront-guided custom ablation for myopia using the NIDEK NAVEX laser system. *J Refract Surg* 2008;24(5):487–493

23 Villarrubia A, Palacín E, Bains R, Gersol J. Comparison of custom ablation and conventional laser *in situ* keratomileusis for myopia and myopic astigmatism using the Alcon excimer laser. *Cornea* 2009;28(9):971–975

24 Hashemian SJ, Aghaei H, Foroutan A, Ghaempanah M, Jafari ME. Laser *in situ* keratomileusis versus laser assisted subepithelial keratectomy for the correction of low to moderate myopia and astigmatism. *Iranian Journal of Ophthalmology* 2012;24(4):31–39

25 Kohnen T, Bühren J, Kühne C, Mirshahi A. Wavefront-guided LASIK with the Zyoptix 3.1 system for the correction of myopia and compound myopic astigmatism with 1-year follow-up: clinical outcome and change in higher order aberrations. *Ophthalmology* 2004;111(12):2127–2185

26 de Benito-Llopis L, Teus MA, Gil-Cazorla R, Drake P. Comparison between femtosecond laser-assisted sub-Bowman keratomileusis *vs* laser subepithelial keratectomy to correct myopia. *Am J Ophthalmol* 2009;148(6):830–836

27 Sia RK, Coe CD, Edwards JD, Ryan DS, Bower KS. Visual outcomes after Epi-LASIK and PRK for low and moderate myopia. *J Refract Surg* 2012;28(1):65–71

28 Teus MA, de Benito-Llopis L, García-González M. Comparison of visual results between laser-assisted subepithelial keratectomy and epipolis laser *in situ* keratomileusis to correct myopia and myopic astigmatism. *Am J Ophthalmol* 2008;146(3):357–362